Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted ...

The ruling maintains access to the drug while litigation continues. Mifepristone can still be prescribed at pharmacies or by ...

A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way ...

Nearly two years after splitting off from Bluebird bio, cancer drug developer 2Seventy bio is cutting 40% of its workforce and reducing spending in a restructuring meant to fund its operations into at ...

The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the ...

Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA ...

A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.

Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly ...

Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.

Generate Biomedicines on Thursday said it has raised another $273 million to fund its pipeline of drugs for autoimmune disorders, cancers and infectious diseases. The startup, incubated by Flagship ...

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...